Experts call for greater understanding of ‘bedwetting’ as a medical condition
- Bedwetting, also known as enuresis, is an uncontrollable leakage of urine while asleep1
- Bedwetting is common in children, with approximately 5–10% of 7-year-olds regularly wetting their beds and the problem may persist into teenage and adulthood2
- In most cases, bedwetting is a complex medical condition caused by over-production of urine at night or reduced capacity of the bladder, which can impact a child’s overall self-esteem, emotional well-being and day time functioning1 , 3
SAINT-PREX, Switzerland, May 27, 2019 (GLOBE NEWSWIRE) -- Recent survey findings highlighted there are misconceptions underlying bedwetting, a condition that is under-recognised and misunderstood by society and healthcare professionals.3,4 A frequent misconception of bedwetting is that the cause is psychological, rather than having a multifactorial pathophysiological basis.1 , 4 Furthermore, the survey revealed that not only parents but also health care providers share this misconception and treatment was not necessarily consistent with guidelines.4
“For physicians to effectively treat bedwetting, any existing behavioural issues must be managed as a separate condition,” said Dr. Michal Maternik, Department of Urology, Division of Paediatric Urology, Medical University of Gdansk, Poland. “The survey findings highlight the need for new educational initiatives to optimise the understanding of bedwetting and provision of care amongst the medical community, parents and the public.”
Bedwetting can lead to feelings of shame and low self-esteem, preventing many patients from seeking treatment.3 , 4 According to the new survey, patients and their respected caregivers reported bedwetting to be associated with behavioural difficulties including, ‘sustaining attention’ (28%), ‘maintaining attention at school’ (29%), and sleeping difficulties (21%) resulting in repercussions on school performance.4 These consequences are often prolonged as many parents seek lifestyle changes first and nearly half of them do not seek help in children five years or older.4
“For decades, bedwetting was considered as a simple condition that would resolve spontaneously,” said Professor Serdar Tekgül at the Department of Urology at Hacettepe University, Turkey. “Bedwetting is now regarded as a complex disorder involving several factors such as bladder dysfunction, and the over-production of urine at night”.
The survey was completed by physicians and patients in Alpe-Adria, Italy, Romania, Russia, Serbia and Slovakia on their understanding of the medical condition, its impact on the lives of patients and the prevalence of comorbidities.4
Bedwetting, also known as enuresis, is an uncontrollable leakage of urine while asleep in children from aged 5 years.1 In most cases it is caused by over-production of urine at night or reduced capacity of the bladder.2 An inability to wake up can be another cause.2 Bedwetting does not have a psychological cause.1 Bedwetting is a common childhood medical condition, with approximately 5–10% of 7 year-olds regularly wetting their beds and the problem may persist into teenage and adulthood.2
About World Bedwetting Day
World Bedwetting Day was initiated to raise awareness among the public and healthcare professionals that bedwetting is a common medical condition that can and should be treated. World Bedwetting Day 2019 will take place on 28th May 2019 and occurs on the last Tuesday of May each year. The theme is: ‘Time to Take Action’, in recognition that much more can be done to diagnose and treat those children who suffer from bedwetting.
For more information please visit www.worldbedwettingday.com.
About the World Bedwetting Day Steering Committee
The World Bedwetting Day Steering Committee brings together experts from across the globe to support this initiative and consists of the International Children’s Continence Society (ICCS), the European Society of Paediatric Urology (ESPU), the Asia Pacific Association of Paediatric Urology (APAPU), the International Paediatric Nephrology Association (IPNA), the European Society of Paediatric Nephrology (ESPN), the Sociedad Iberoamericana de Urologia Paediatrica (SIUP), the North American Paediatric Urology Societies, ERIC (The Children's Bowel & Bladder Charity) and Bladder & Bowel UK. The initiative is supported by Ferring Pharmaceuticals.
1 Theunis M et al. Self-Image and Performance in Children with Nocturnal Enuresis. European Urology. 2002; 41:660-667
2 Nevéus T. Nocturnal enuresis—theoretic background and practical guidelines. Pediatr Nephrol. 2011; 26:1207–1214
3 Vande Walle J et al, Practical consensus guidelines for the management of enuresis. Eur J Pediatr 2012;171:971-983
4 Maternik. Understanding of and misconceptions around monosymptomatic nocturnal enuresis: findings from patient and physician surveys. Journal of Pediatric Urology 2018
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8147ae15-92f1-41ed-a13a-b1db5f6df6ec
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration23.8.2019 22:01:00 CEST | Press release
Foster City, Calif. and Mechelen, Belgium; 23 August 2019; 22.01 CET; regulated information – Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on 14 July 2019. This agreement has received clearance from the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and merger control approval from the Austrian Federal Competition Authority. Under the terms of the agreement, the closing of this transaction triggers an upfront license fee payment of $3.95 billion by Gilead to Galapagos. In addition, Gilead has made an equity investment in Galapagos of approximately $1.1 billion (or approximately €960 million) by subscribing for new shares at a price of €140.59 per share, including issuance premium. As a result, Gilead now owns 13,589,686 ordinary shares of Galapagos, representing approximately 22 percent of the currently outsta
EVS Broadcast Equipment strikes major deal with NEP to upgrade their US production activities23.8.2019 18:00:00 CEST | Press release
Publication on August 23 2019, 06:00 P.M. CET Regulated information – Privileged information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS STRIKES MAJOR DEAL WITH NEP TO UPGRADE THEIR US PRODUCTION ACTIVITIES EVS Broadcast Equipment, the leading provider of live production solutions, today announces that NEP is investing over $8m to deploy the next generation EVS live video production server as part of their US inventory. Liège, Belgium, August 23, 2019 EVS, the leading provider of live production solutions, has been selected by NEP, an international production company serving live broadcasting throughout the world, to deliver a major upgrade and upscale of their production facilities. The deal represents the acquisition of EVS’ XT-VIA next-generation live production servers, as well as the deployment of LSM replay controllers, IPDirector content management solutions and other infrastructure systems. All new systems will be installe
Clinical data on Idorsia's pipeline compounds will be presented at the European Society of Cardiology Congress 201923.8.2019 17:35:00 CEST | Press release
Allschwil, Switzerland – August 23, 2019 Idorsia Ltd (SIX: IDIA) today announced that data from Phase 2 studies with aprocitentan, a new dual endothelin receptor antagonist, and selatogrel, a highly-selective P2Y12 receptor antagonist, will be shared during the European Society of Cardiology (ESC) Congress 2019 in Paris, France. Idorsia’s aprocitentan An oral presentation entitled "Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension", will be part of the "Drug treatment in hypertension - New insights" session with a focused discussion with the lead author, Dr Parisa Danaietash from Idorsia, at 09:54 on August 31, 2019. The abstract can be found online. Idorsia’s selatogrel An oral presentation entitled "Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients", will be part of th
Millicom - H1 2019 Consolidated Financial Statements23.8.2019 16:53:00 CEST | Press release
Millicom’s H1 2019 Consolidated Financial Statements Luxembourg, August 23, 2019— Millicom, a leading provider of cable and mobile services operating under the TIGO brand in Latin America, has published its H1 2019 consolidated financial statements. Contents include: • Management Report • Responsibility Statement • Review Report of the Independent Auditors • Unaudited Interim Condensed Consolidated Financial Statements -END- For further information, please contact Press: Vivian Kobeh, Corporate Communications Director +1 786-628-5300 email@example.com Investors: Michel Morin, VP Investor Relations +1 786-628-5270 firstname.lastname@example.org Sarah Inmon, Investor Relations Manager +1-786-628-5303 email@example.com About Millicom Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of cable and mobile services dedicated to emerging markets in Latin America and Africa. Millicom sets the pace when it comes to providing high-speed broadband and innovation around T
Banks net position in the Riksbank23.8.2019 16:42:00 CEST | Press release
AUG 23, 2019 SEK MILLION LENDING BORROWING 265
Conditions for Riksbank Bid Procedures Sek Bonds23.8.2019 16:20:00 CEST | Press release
Sveriges Riksbank Bid procedure details Government Bonds, 2019-08-29 Maturity date Loan ISIN code Coupon Volume, SEK million 2025-05-12 1058 SE0005676608 2.50 % 500 +/- 250 2039-03-30 1053 SE0002829192 3.50 % 500 +/- 250 Settlement date 2019-09-02 Bids have to be entered by 10.00 on AUG 29, 2019 Highest permitted bid volume: 500 SEK million in issue SGB 1058 and 500 SEK million in issue SGB 1053 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST) ON AUG 29, 2019. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se